Regulus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Regulus Therapeutics

13/05/2022 16:28

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted
loss of 5 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 5 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 5 cents​.
    * The mean earnings estimate of analysts had risen by
about 15.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Regulus Therapeutics Inc shares had fallen by 17.6% this
quarter and lost 22.0% so far this year.
    * The company reported a quarterly loss of $6.72 million.
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $2.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 13 at 03:28 p.m.  ​All
figures in US dollars unless otherwise stated